Shandong Weigao Group Medical Polymer Company Limited provided earnings guidance for the year ended 31 December 2023. For the year, the company expects to record a decrease in revenue in the range of 2% to 5% during the Reporting Period as compared with the revenue recognised due to the accounting restatement as a result of business combination under common control for the same period last year; and a decrease of net profit attributable to the owners of the Company for the Reporting Period in the range of 25% to 30% as compared with the Net Profit reported with consideration of the accounting restatement as a result of business combination under common control for the same period last year.
Shandong Weigao Group Medical Polymer Company Limited
Equities
1066
CNE100000171
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.35 HKD | -0.56% | +0.19% | -29.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.70% | 3.15B | |
+7.33% | 28.33B | |
-14.71% | 2.57B | |
+21.58% | 2.55B | |
+7.41% | 2.09B | |
-3.87% | 2.04B | |
+0.56% | 1.53B | |
+2.15% | 1.33B | |
+23.78% | 1.23B | |
+4.72% | 1.16B |
- Stock Market
- Equities
- 1066 Stock
- News Shandong Weigao Group Medical Polymer Company Limited
- Shandong Weigao Group Medical Polymer Company Limited Provides Earnings Guidance for the Year Ended 31 December 2023